[96a5a0]: / output / allTrials / identified / NCT06791460_identified.json

Download this file

860 lines (860 with data), 38.3 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
{
"info": {
"nct_id": "NCT06791460",
"official_title": "Pegylated Liposomal Doxorubicin Plus Adebrelimab with or Without Mirabegron in Relapsed Ovarian Cancer: a Randomized, Controlled, Open-label Trial",
"inclusion_criteria": "* Has provided documented informed consent for the study.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Has histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.\n* Has received a front line platinum-based regimen (administered via either intravenous or intraperitoneal route) per local standard of care or treatment guideline following the primary or interval debulking surgery with documented disease recurrence (note: Maintenance treatment following the front line treatment is permitted and counted together as part of the front line treatment).\n* Has a platinum-free interval (PFI) of < 12 months if the last regimen received is a platinum-based, or a treatment-free interval (TFI) of < 12 months if the last regimen received is a non-platinum-based.\n* Has measurable disease at baseline based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n* Has a life expectancy of ≥12 weeks.\n* Has provided a tumor tissue sample either collected from prior cytoreductive surgery or fresh newly obtained tumor tissue at screening.\n* Has adequate organ function.\n* Has not recovered from AEs to ≤ Grade 1 or prior treatment level due to a previously administered agent.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
"exclusion_criteria": "* Has nonepithelial cancers, borderline tumors, mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor and undifferentiated carcinoma.\n* Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated antigen-4 [CTLA-4], tumor necrosis factor receptors OX-40 or CD137) or has participated in prior adebrelimab studies.\n* Has received prior systemic anticancer therapy including radiation therapy or maintenance therapy within 4 weeks before randomization.\n* Has severe hypersensitivity (≥Grade 3) or uncontrolled hypertension to pegylated liposomal doxorubicin, adebrelimab, mirabegron and any of their excipients.\n* Has undergone major surgery within 3 weeks before randomization or has complications/sequelae that have not yet recovered.\n* Has a known additional malignancy that progressed or required active treatment within the last 5 years.\n* Is pregnant or breastfeeding.\n* Has a history of allogenic tissue/solid organ transplant.\n* Has a history of thrombotic disorders, hemorrhage, hemoptysis, or active gastrointestinal bleeding within 6 months before randomization.\n* Has a history of active autoimmune disease.\n* Has an active infection requiring systemic therapy.\n* Has a history of human immunodeficiency virus (HIV) infection.\n* Has a history of Hepatitis B or C virus infection.\n* Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study.\n* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Has provided documented informed consent for the study.",
"criterions": [
{
"exact_snippets": "Has provided documented informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "documentation",
"expected_value": true
}
]
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
]
}
]
},
{
"line": "* Has histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.",
"criterions": [
{
"exact_snippets": "histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma",
"criterion": "carcinoma type",
"requirements": [
{
"requirement_type": "presence",
"expected_value": [
"epithelial ovarian",
"fallopian tube",
"primary peritoneal"
]
}
]
}
]
},
{
"line": "* Has received a front line platinum-based regimen (administered via either intravenous or intraperitoneal route) per local standard of care or treatment guideline following the primary or interval debulking surgery with documented disease recurrence (note: Maintenance treatment following the front line treatment is permitted and counted together as part of the front line treatment).",
"criterions": [
{
"exact_snippets": "Has received a front line platinum-based regimen",
"criterion": "front line platinum-based regimen",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
},
{
"exact_snippets": "administered via either intravenous or intraperitoneal route",
"criterion": "route of administration",
"requirements": [
{
"requirement_type": "route",
"expected_value": [
"intravenous",
"intraperitoneal"
]
}
]
},
{
"exact_snippets": "per local standard of care or treatment guideline",
"criterion": "adherence to local standard of care or treatment guideline",
"requirements": [
{
"requirement_type": "adherence",
"expected_value": true
}
]
},
{
"exact_snippets": "following the primary or interval debulking surgery",
"criterion": "timing relative to surgery",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "following primary or interval debulking surgery"
}
]
},
{
"exact_snippets": "with documented disease recurrence",
"criterion": "disease recurrence",
"requirements": [
{
"requirement_type": "documentation",
"expected_value": true
}
]
}
]
},
{
"line": "* Has a platinum-free interval (PFI) of < 12 months if the last regimen received is a platinum-based, or a treatment-free interval (TFI) of < 12 months if the last regimen received is a non-platinum-based.",
"criterions": [
{
"exact_snippets": "platinum-free interval (PFI) of < 12 months if the last regimen received is a platinum-based",
"criterion": "platinum-free interval",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": "<",
"value": 12,
"unit": "months"
}
},
{
"requirement_type": "last regimen type",
"expected_value": "platinum-based"
}
]
},
{
"exact_snippets": "treatment-free interval (TFI) of < 12 months if the last regimen received is a non-platinum-based",
"criterion": "treatment-free interval",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": "<",
"value": 12,
"unit": "months"
}
},
{
"requirement_type": "last regimen type",
"expected_value": "non-platinum-based"
}
]
}
]
},
{
"line": "* Has measurable disease at baseline based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.",
"criterions": [
{
"exact_snippets": "Has measurable disease at baseline based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.",
"criterion": "measurable disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
},
{
"requirement_type": "evaluation criteria",
"expected_value": "Response Evaluation Criteria in Solid Tumors (RECIST) 1.1"
}
]
}
]
},
{
"line": "* Has a life expectancy of ≥12 weeks.",
"criterions": [
{
"exact_snippets": "life expectancy of ≥12 weeks",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Has provided a tumor tissue sample either collected from prior cytoreductive surgery or fresh newly obtained tumor tissue at screening.",
"criterions": [
{
"exact_snippets": "provided a tumor tissue sample",
"criterion": "tumor tissue sample",
"requirements": [
{
"requirement_type": "availability",
"expected_value": true
}
]
},
{
"exact_snippets": "collected from prior cytoreductive surgery",
"criterion": "tumor tissue sample source",
"requirements": [
{
"requirement_type": "source",
"expected_value": "prior cytoreductive surgery"
}
]
},
{
"exact_snippets": "fresh newly obtained tumor tissue at screening",
"criterion": "tumor tissue sample source",
"requirements": [
{
"requirement_type": "source",
"expected_value": "fresh newly obtained at screening"
}
]
}
]
},
{
"line": "* Has adequate organ function.",
"criterions": [
{
"exact_snippets": "adequate organ function",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Has not recovered from AEs to ≤ Grade 1 or prior treatment level due to a previously administered agent.",
"criterions": [
{
"exact_snippets": "Has not recovered from AEs to ≤ Grade 1",
"criterion": "adverse events (AEs) recovery",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "Grade"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "value",
"expected_value": "female"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 75 Years",
"criterions": [
{
"exact_snippets": "maximum age of 75 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 75,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Has nonepithelial cancers, borderline tumors, mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor and undifferentiated carcinoma.",
"criterions": [
{
"exact_snippets": "nonepithelial cancers",
"criterion": "nonepithelial cancers",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "borderline tumors",
"criterion": "borderline tumors",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "mucinous",
"criterion": "mucinous tumors",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "seromucinous that is predominantly mucinous",
"criterion": "seromucinous tumors",
"requirements": [
{
"requirement_type": "predominance",
"expected_value": "mucinous"
}
]
},
{
"exact_snippets": "malignant Brenner's tumor",
"criterion": "malignant Brenner's tumor",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "undifferentiated carcinoma",
"criterion": "undifferentiated carcinoma",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated antigen-4 [CTLA-4], tumor necrosis factor receptors OX-40 or CD137) or has participated in prior adebrelimab studies.",
"criterions": [
{
"exact_snippets": "Has received prior therapy with an anti-programmed cell death (PD)-1",
"criterion": "prior therapy with anti-PD-1",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Has received prior therapy with ... anti-PD-L1",
"criterion": "prior therapy with anti-PD-L1",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Has received prior therapy with ... anti-PD-L2",
"criterion": "prior therapy with anti-PD-L2",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Has received prior therapy with ... agent directed to another co-inhibitory T-cell receptor",
"criterion": "prior therapy with agent directed to co-inhibitory T-cell receptor",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Has received prior therapy with ... cytotoxic T-lymphocyte-associated antigen-4 [CTLA-4]",
"criterion": "prior therapy with CTLA-4",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Has received prior therapy with ... tumor necrosis factor receptors OX-40",
"criterion": "prior therapy with OX-40",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Has received prior therapy with ... tumor necrosis factor receptors ... CD137",
"criterion": "prior therapy with CD137",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "has participated in prior adebrelimab studies",
"criterion": "participation in prior adebrelimab studies",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has received prior systemic anticancer therapy including radiation therapy or maintenance therapy within 4 weeks before randomization.",
"criterions": [
{
"exact_snippets": "Has received prior systemic anticancer therapy",
"criterion": "prior systemic anticancer therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "including radiation therapy",
"criterion": "prior radiation therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "maintenance therapy",
"criterion": "prior maintenance therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "within 4 weeks before randomization",
"criterion": "time since last therapy",
"requirements": [
{
"requirement_type": "time since last therapy",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Has severe hypersensitivity (≥Grade 3) or uncontrolled hypertension to pegylated liposomal doxorubicin, adebrelimab, mirabegron and any of their excipients.",
"criterions": [
{
"exact_snippets": "severe hypersensitivity (≥Grade 3) ... to pegylated liposomal doxorubicin, adebrelimab, mirabegron and any of their excipients",
"criterion": "hypersensitivity to pegylated liposomal doxorubicin, adebrelimab, mirabegron and any of their excipients",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "Grade"
}
}
]
},
{
"exact_snippets": "uncontrolled hypertension to pegylated liposomal doxorubicin, adebrelimab, mirabegron and any of their excipients",
"criterion": "hypertension to pegylated liposomal doxorubicin, adebrelimab, mirabegron and any of their excipients",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
}
]
}
]
},
{
"line": "* Has undergone major surgery within 3 weeks before randomization or has complications/sequelae that have not yet recovered.",
"criterions": [
{
"exact_snippets": "Has undergone major surgery within 3 weeks before randomization",
"criterion": "major surgery",
"requirements": [
{
"requirement_type": "time since surgery",
"expected_value": {
"operator": "<=",
"value": 3,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "has complications/sequelae that have not yet recovered",
"criterion": "complications/sequelae",
"requirements": [
{
"requirement_type": "recovery status",
"expected_value": false
}
]
}
]
},
{
"line": "* Has a known additional malignancy that progressed or required active treatment within the last 5 years.",
"criterions": [
{
"exact_snippets": "known additional malignancy",
"criterion": "additional malignancy",
"requirements": [
{
"requirement_type": "progression",
"expected_value": true
},
{
"requirement_type": "treatment",
"expected_value": {
"operator": "<=",
"value": 5,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Is pregnant or breastfeeding.",
"criterions": [
{
"exact_snippets": "Is pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "breastfeeding",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Has a history of allogenic tissue/solid organ transplant.",
"criterions": [
{
"exact_snippets": "Has a history of allogenic tissue/solid organ transplant.",
"criterion": "allogenic tissue/solid organ transplant",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Has a history of thrombotic disorders, hemorrhage, hemoptysis, or active gastrointestinal bleeding within 6 months before randomization.",
"criterions": [
{
"exact_snippets": "history of thrombotic disorders",
"criterion": "thrombotic disorders",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "history of ... hemorrhage",
"criterion": "hemorrhage",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "history of ... hemoptysis",
"criterion": "hemoptysis",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "active gastrointestinal bleeding within 6 months before randomization",
"criterion": "gastrointestinal bleeding",
"requirements": [
{
"requirement_type": "activity",
"expected_value": true
},
{
"requirement_type": "time frame",
"expected_value": "within 6 months before randomization"
}
]
}
]
},
{
"line": "* Has a history of active autoimmune disease.",
"criterions": [
{
"exact_snippets": "Has a history of active autoimmune disease.",
"criterion": "autoimmune disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
},
{
"requirement_type": "activity",
"expected_value": "active"
}
]
}
]
},
{
"line": "* Has an active infection requiring systemic therapy.",
"criterions": [
{
"exact_snippets": "active infection requiring systemic therapy",
"criterion": "infection",
"requirements": [
{
"requirement_type": "activity",
"expected_value": "active"
},
{
"requirement_type": "treatment",
"expected_value": "systemic therapy"
}
]
}
]
},
{
"line": "* Has a history of human immunodeficiency virus (HIV) infection.",
"criterions": [
{
"exact_snippets": "Has a history of human immunodeficiency virus (HIV) infection.",
"criterion": "HIV infection",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Has a history of Hepatitis B or C virus infection.",
"criterions": [
{
"exact_snippets": "Has a history of Hepatitis B",
"criterion": "Hepatitis B virus infection",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "Has a history of ... C virus infection",
"criterion": "Hepatitis C virus infection",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study.",
"criterions": [
{
"exact_snippets": "Has a history or current evidence of any condition",
"criterion": "condition",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Has a history or current evidence of any ... therapy",
"criterion": "therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Has a history or current evidence of any ... laboratory abnormality",
"criterion": "laboratory abnormality",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Has a history or current evidence of any ... other circumstance",
"criterion": "other circumstance",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.",
"criterions": [
{
"exact_snippets": "known psychiatric ... disorder",
"criterion": "psychiatric disorder",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "known ... substance abuse disorder",
"criterion": "substance abuse disorder",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}